Market Overview

Neurotrope Falls 55% After Alzheimer's Drug Results Come Under Scrutiny

Share:
Related
25 Stocks Moving In Monday's Pre-Market Session
40 Biggest Movers From Friday

Neurotrope Inc (NASDAQ: NTRP) shares are trading lower by $10.50 (55 percent) or 55 percent at $8.31 in Monday's session after Phase 2 results came out less than positive.

The issue is in a freefall after Adam Feuerstein spoke on Benzinga's PreMarket Prep and exposed the actual results of what the company deemed as a positive for Bryostatin for the treatment for Alzheimer's disease.

See Also: Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance

Adding to the selling pressure is Friday's who anticipated good results and purchased shares  during its rally from Thursday's close of $15.13 to $18.81.

After being pounded in the pre-market session, Neurotrope's stock could only manage a nickel bounce of its nearly $9.00 lower opening print to $10.05 before continuing its move lower.

So far, the ensuing decline has taken the stock to $8.16 and it's attempting to mount a rebound. Despite the rout in today's session, the issue is still in the green for 2017, as it ended 2016 at $7.52.

Posted-In: Technicals Intraday Update Movers Trading Ideas

 

Related Articles (NTRP)

View Comments and Join the Discussion!